Stephen J. Farr, Ph.D. is one of our co-founders, a member of our board of directors and has served as our Chief Executive Officer since April 2015, leading our strategy on developing drugs in rare orphan neurological disorders.  In his original role as President and Chief Operating Officer since the founding of Zogenix in 2006, Dr. Farr led the development and FDA approval of the Company’s first two drug products.  Prior to starting Zogenix, Dr. Farr held positions of increasing responsibility at Aradigm Corporation from 1995 to 2006.  His last position was Aradigm’s Sr. Vice President and Chief Scientific Officer, with responsibility for research and development as well as business development.  From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of biopharmaceutics. While there, he built an internationally recognized research group working in drug delivery science with a focus on pulmonary drug delivery.

Dr. Farr is a member of the board of directors of SteadyMed (NASDAQ: STDY) and two private companies, Oscillari, LLC and Flow Pharma, Inc.  He is author/co-author of over 180 scientific publications and patents and retains his academic interests as adjunct Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, USA.  Dr. Farr received a BSc (Hons) Pharmacy degree from De Montfort University, UK and holds his Ph.D. degree in Pharmaceutics from the University of Wales.

Gail M. Farfel, Ph.D., has served as our Executive Vice President and Chief Development Officer since July 2015. Prior to joining Zogenix, Dr. Farfel was Chief Clinical and Regulatory Officer of Marinus Pharmaceuticals, establishing and overseeing clinical, medical and regulatory strategies for adult and pediatric seizure disorders, including a pediatric epileptic orphan disease. Previously, Dr. Farfel was Vice President, Therapeutic Area and Head for Neuroscience Clinical Development and Medical Affairs at Novartis Pharmaceuticals Corporation, where she oversaw a portfolio of products including Gilenya® for multiple sclerosis, Exelon® and the Exelon® Patch for Alzheimer's disease and Parkinson's disease, and the antidepressant, agomelatine. Dr. Farfel began her career in pharmaceutical drug development at Pfizer, Inc., where she worked in Clinical Development and Global Medical Affairs, directing programs through all stages of clinical development and regulatory submissions. Dr. Farfel is the author of over 50 scientific articles in the areas of neuropsychopharmacology and drug effects, and holds a Ph.D. in Neuropsychopharmacology from the University of Chicago, where she received the Ginsburg Prize for Dissertation Excellence. Dr. Farfel also holds a Bachelor's degree in Biochemistry from the University of Virginia.

Bradley S. Galer, M.D., has served as our Executive Vice President and Chief Medical Officer since December 2013. Prior to joining Zogenix, Dr. Galer served as President of the Pain Group at Nuvo Research, a specialty pharmaceutical company with three commercialized topically delivered pain products. In this position, he oversaw the strategy and operations of the Pain Group, including its commercialization, drug development activities, business development and licensing opportunities and liaising with partners. Prior to joining Nuvo, Dr. Galer was employed at Endo Pharmaceuticals as Senior Medical Officer and Group Vice President, Scientific Affairs, where he was responsible for the departments of Clinical and Biostatistics, Medical Affairs, Pharmacovigilance, Medical Liaison and Medical Information. He and his team provided clinical and scientific leadership for the development and marketing of analgesic and migraine products, including Lidoderm, Percocet, Opana, Opana ER and Frova. Dr. Galer has also held numerous other industry positions, along with academic and clinical appointments. He has published over 200 articles on pain management in peer review journals and textbooks. Dr. Galer received his medical doctorate and a neurology residency from Albert Einstein in New York and two Pain Fellowships, at Memorial Sloane-Kettering in New York and University of California San Francisco, as well as headache training at Montefiore Headache Clinic in New York and University of California San Francisco.

Ashish Sagrolikar has served as our Executive Vice President and Chief Commercial Officer since July 2018. He is an accomplished commercial leader whose experience spans four continents, including the United States. Prior to joining Zogenix, Mr. Sagrolikar was Vice President of Commercial Transformation and Vice President of Immunology Marketing & Rare Disease at GlaxoSmithKline, where he led the efforts to develop a rare disease business unit building a nimble operating model for specialty therapies, including the launch of BENLYSTA SC, a therapy for lupus, and acquisition of future assets. Previously, he was Vice President, Sales and Marketing for the U.S. hemophilia franchise at Baxter International before being promoted to Vice President, Business Development of Baxter BioScience. At Baxter he led teams that successfully launched multiple products for rare conditions, including ADVATE, FEIBA NF, GAMMAGARD Liquid, and Aralast NP, among many others. Mr. Sagrolikar's other accomplishments include being a founding member of Baxter's Global Inclusion Council, which championed the development of women and minorities in leadership positions. He has authored and presented peer-reviewed analyses on access to healthcare for patients in developing countries. Mr. Sagrolikar earned his MBA at the Institute of Management Development (IMD), Lausanne, Switzerland, and holds a Bachelor of Pharmacy from the Government College of Pharmacy, Karad, India.

Michael P. Smith has served as our Executive Vice President, Chief Financial Officer, Treasurer and Secretary since January 2017. From January 2015 through December 2016, Mr. Smith served as Chief Financial Officer of Raptor, a global biopharmaceutical company focused on the development and commercialization of transformative therapeutics for rare diseases that was acquired by Horizon Pharma plc.  In this role, he was responsible for the finance, accounting, corporate development, corporate strategy, intellectual property, and information management business functions. From May 2012 to January 2015, Mr. Smith served as Chief Financial and Business Advisor at Catalyst Biosciences.  Prior to that role, he was Vice President of Business Development at iPierian, Inc., and from June 2006 to July 2009, served as Head of Business Development and Chief Financial Officer of Memory Pharmaceuticals Corporation.  Mr. Smith received a B.S. in Commerce from the University of Virginia and an M.B.A. from the Haas School of Business at the University of California, Berkeley.